DAFTAR PUSTAKA

Addisu, F. *et al.* (2015) 'Length of stay of psychiatric admissions in a general hospital in Ethiopia: A retrospective study', *International Journal of Mental Health Systems*, 9(1), pp. 1–9. doi: 10.1186/s13033-015-0006-x.

Ahn, E. and Kang, H. (2018) 'Introduction to systematic review and meta-analysis', *Korean Journal of Anesthesiology*, 71(2), pp. 103–112. doi: 10.4097/kjae.2018.71.2.103.

Baeza, F. L. C., Da Rocha, N. S. and Fleck, M. P. (2018) 'Predictors of length of stay in an acute psychiatric inpatient facility in a general hospital: A prospective study', *Revista Brasileira de Psiquiatria*, 40(1), pp. 89–96. doi: 10.1590/1516-4446-2016-2155.

Chan, H. Y. *et al.* (2013) 'An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation', *Journal of Clinical Psychopharmacology*, 33(6), pp. 747–752. doi: 10.1097/JCP.0b013e31829e8168.

Charlson, F. J. *et al.* (2018) 'Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016', *Schizophrenia Bulletin*, 44(6), pp. 1195–1203. doi: 10.1093/schbul/sby058.

Chen, S. *et al.* (2017) 'Patient Characteristics, Length of Stay, and Functional Improvement for Schizophrenia Spectrum Disorders: A Population Study of Inpatient Care in Ontario 2005 to 2015', *Canadian Journal of Psychiatry*, 62(12), pp. 854–863. doi: 10.1177/0706743716680167.

Chien, W. T. and Yip, A. L. K. (2013) 'Current approaches to treatments for schizophrenia spectrum disorders, part I: An overview and medical treatments', *Neuropsychiatric Disease and Treatment*, 9, pp. 1311–1332. doi: 10.2147/NDT.S37485.

Citrome, L. *et al.* (2016) 'The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: Results from a randomized, exploratory study', *International Clinical Psychopharmacology*, 31(4), pp. 192–201. doi: 10.1097/YIC.0000000000000123.

Davis, J. *et al.* (2016) 'HHS Public Access', pp. 185–194. doi: 10.1016/j.neubiorev.2016.03.017.A.

Faay, M. D. M., Czobor, P. and Sommer, I. E. C. (2018) 'Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis', *Neuropsychopharmacology*. Springer US, 43(12), pp. 2340–2349. doi: 10.1038/s41386-018-0161-2.

Gage, S. H. and Munafò, M. R. (2015) 'Smoking as a causal risk factor for schizophrenia', *The Lancet Psychiatry*, 2(9), pp. 778–779. doi: 10.1016/S2215-

0366(15)00333-8.

Ganguly, P., Soliman, A. and Moustafa, A. A. (2018) 'Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment', *Frontiers in Public Health*, 6(June). doi: 10.3389/fpubh.2018.00166.

Glick, H. A., Li, P. and Harvey, P. D. (2015) 'The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial', *Schizophrenia Research*. Elsevier B.V., 166(1–3), pp. 110–114. doi: 10.1016/j.schres.2015.05.021.

Gorwood, P. (2011) 'Factors associated with hospitalisation of patients with schizophrenia in four European countries', *European Psychiatry*, 26(4), pp. 224–230. doi: 10.1016/j.eurpsy.2011.02.012.

Graham, S. M. *et al.* (2011) 'Risk of osteoporosis and fracture incidence in patients on antipsychotic medication', *Expert Opinion on Drug Safety*, 10(4), pp. 575–602. doi: 10.1517/14740338.2011.560112.

Haller, C. S. *et al.* (2014) 'Recent advances in understanding schizophrenia', *F1000Prime Reports*, 6(July), pp. 1–11. doi: 10.12703/P6-57.

Hermes, E. D. a. *et al.* (2013) 'Minimum Clinically Important Difference In The Positive And Negative Syndrome Scale Using Data From The CATIE Schizophrenia Trial', *J Clin Psychiatry*, 73(4), pp. 526–532. doi: 10.4088/JCP.11m07162.Minimum.

Herz, M. I. *et al.* (2010) 'Practice guideline for the treatment of patients with schizophrenia', *American Journal of Psychiatry*, 154(4 SUPPL.), pp. 1–63. doi: 10.1176/ajp.154.4.1.

Higuchi, T. *et al.* (2019) 'Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial', *Asia-Pacific Psychiatry*, 11(3). doi: 10.1111/appy.12354.

Ih, H., Putri, R. A. and Untari, E. K. (2016) 'Different Type of Antipsychotic Therapies on Length of Stay of Acute Schizophrenia Patients in Sungai Bangkong Regional Mental Hospital Pontianak', *Indonesian Journal of Clinical Pharmacy*, 5(2), pp. 115–122. doi: 10.15416/ijcp.2016.5.2.115.

Jacobs, R. *et al.* (2015) 'Determinants of hospital length of stay for people with serious mental illness in England and implications for payment systems: A regression analysis', *BMC Health Services Research*. BMC Health Services Research, 15(1), pp. 1–16. doi: 10.1186/s12913-015-1107-6.

Kapur, S. *et al.* (2006) 'How antipsychotics work - From receptors to reality', *NeuroRx*, 3(1), pp. 10–21. doi: 10.1016/j.nurx.2005.12.003.

Karama, S. *et al.* (2015) 'Cigarette smoking and thinning of the brain's cortex', *Molecular Psychiatry*. Nature Publishing Group, 20(6), pp. 778–785. doi: 10.1038/mp.2014.187.

Kashani, L. *et al.* (2017) 'Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial', *Journal of Psychiatric Research*. Elsevier Ltd, 94, pp. 70–77. doi: 10.1016/j.jpsychires.2017.06.011.

Kim, D. W. *et al.* (2017) 'Estimation of symptom severity scores for patients with schizophrenia using ERP source activations during a facial affect discrimination task', *Frontiers in Neuroscience*, 11(AUG), pp. 1–6. doi: 10.3389/fnins.2017.00436.

Kishi, T. *et al.* (2013) 'Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: Results from a 12-week, flexible dose study using raters masked to antipsychotic choice', *Asian Journal of Psychiatry*. Elsevier B.V., 6(3), pp. 200–207. doi: 10.1016/j.ajp.2012.10.007.

Kozma, C. M. *et al.* (2010) 'Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: Pooled analysis of a clinical trial extension', *Annals of General Psychiatry*, 9, pp. 1–8. doi: 10.1186/1744-859X-9-24.

Lefort-Besnard, J. *et al.* (2018) 'Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire', *Translational Psychiatry*. Springer US, 8(1). doi: 10.1038/s41398-018-0294-4.

Lin, Chieh Hsin *et al.* (2018) 'Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial', *Biological Psychiatry*. Society of Biological Psychiatry, 84(6), pp. 422–432. doi: 10.1016/j.biopsych.2017.12.006.

Loebel, A. *et al.* (2013) 'Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial', *Schizophrenia Research*. Elsevier B.V., 145(1–3), pp. 101–109. doi: 10.1016/j.schres.2013.01.009.

Meltzer, H. Y. *et al.* (2011) 'Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study', *American Journal of Psychiatry*, 168(9), pp. 957–967. doi: 10.1176/appi.ajp.2011.10060907.

Morrison, A. P. *et al.* (2018) 'Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial', *The Lancet Psychiatry*, 5(8), pp. 633–643. doi: 10.1016/S2215-0366(18)30184-6.

Omi, T. *et al.* (2017) 'Possible factors influencing the duration of hospital stay in patients with psychiatric disorders attempting suicide by jumping', *BMC Psychiatry*. BMC Psychiatry, 17(1), pp. 1–7. doi: 10.1186/s12888-017-1267-5.

Opler, M. G. A., Yavorsky, C. and Daniel, D. G. (2017) 'Positive and negative syndrome scale (PANSS) training: Challenges, solutions, and future directions', *Innovations in Clinical Neuroscience*, 14(11–12), pp. 77–81.

Østergaard, S. D. *et al.* (2016) 'PANSS-6: A brief rating scale for the measurement of severity in schizophrenia', *Acta Psychiatrica Scandinavica*, 133(6), pp. 436–444. doi: 10.1111/acps.12526.

Patel, K. R. *et al.* (2014) 'Schizophrenia: Overview and treatment options', *P and T*, 39(9), pp. 638–645.

Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia (2011) 'Konsensus Penatalaksanaan Gangguan Skizofrenia', *Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia*, p. 94.

Purwandityo, A. G. *et al.* (2018) 'The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component', *Indonesian Journal of Clinical Pharmacy*, 7(1), pp. 19–29. doi: 10.15416/ijcp.2018.7.1.19.

Pylayeva-Gupta, Y. (2011) 'NIH Public Access', *Bone*, 23(1), pp. 1–7. doi: 10.1038/jid.2014.371.

Rezaei, F. *et al.* (2017) 'Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study', *Human Psychopharmacology*, 32(4), pp. 1–8. doi: 10.1002/hup.2583.

Sørensen, H. J., Jensen, S. O. W. and Nielsen, J. (2013) 'Schizophrenia, antipsychotics and risk of hip fracture: A population-based analysis', *European Neuropsychopharmacology*. Elsevier, 23(8), pp. 872–878. doi: 10.1016/j.euroneuro.2013.04.002.

Stępnicki, P., Kondej, M. and Kaczor, A. A. (2018) 'Current concepts and treatments of schizophrenia', *Molecules*, 23(8). doi: 10.3390/molecules23082087.

Tseng, P. T. *et al.* (2015) 'Bone mineral density in schizophrenia an update of current meta-analysis and literature review under guideline of PRISMA', *Medicine (United States)*, 94(47), p. e1967. doi: 10.1097/MD.0000000000001967.

WHO (2009) 'WHO-AIMS report on mental health system in Jamaica', p. 34. Available at: http://www.who.int/mental_health/Jamaica_who_aims_report.pdf.

Yulianti, Y. (2014) 'Cetak Biru Pelayanan Pasien di Rumah Sakit Jiwa Provinsi Jawa Barat Tahun 2014', *Jurnal Administrasi Rumah Sakit Indonesia*, 1(2), pp. 5–6. doi: 10.1234/arsi.v1i2.2174.

Zamani Esfahlani, F. *et al.* (2017) 'Sensitivity of the positive and negative syndrome scale (PANSS) in detecting treatment effects via network analysis', *Innovations in Clinical Neuroscience*, 14(11–12), pp. 59–67.